Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-2 long-term extension of mirikizumab in Crohn's disease
2022-502841-91-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 31
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoints: Percentage of participants achieving endoscopic response and Percentage of participants achieving clinical remission. Planned start Aug 2020; status: authorised.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-502841-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502841-91-00.